Nautilus Biotechnology (NAUT) Capital Expenditures (QoQ) (2020 - 2026)
Nautilus Biotechnology (NAUT) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Nautilus Biotechnology | 224.14 Mn | 224.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.02% |
| Dec 31, 2025 | -41.63% |
| Sep 30, 2025 | 5.56% |
| Jun 30, 2025 | 80.82% |
| Mar 31, 2025 | -13.78% |
| Dec 31, 2024 | -64.17% |
| Sep 30, 2024 | 38.48% |
| Jun 30, 2024 | -20.87% |
| Mar 31, 2024 | 56.66% |
| Dec 31, 2023 | -52.75% |
| Sep 30, 2023 | 88.77% |
| Jun 30, 2023 | -33.09% |
| Mar 31, 2023 | 202.18% |
| Dec 31, 2022 | -76.22% |
| Sep 30, 2022 | 47.93% |
| Jun 30, 2022 | 35.34% |
| Mar 31, 2022 | -51.22% |
| Dec 31, 2021 | 265.19% |
| Sep 30, 2021 | -49.15% |
| Jun 30, 2021 | 10.17% |